Literature DB >> 23988330

Safety mechanism assisted by the repressor of tetracycline (SMART) vaccinia virus vectors for vaccines and therapeutics.

Patricia Grigg1, Allison Titong, Leslie A Jones, Tilahun D Yilma, Paulo H Verardi.   

Abstract

Replication-competent viruses, such as Vaccinia virus (VACV), are powerful tools for the development of oncolytic viral therapies and elicit superior immune responses when used as vaccine and immunotherapeutic vectors. However, severe complications from uncontrolled viral replication can occur, particularly in immunocompromised individuals or in those with other predisposing conditions. VACVs constitutively expressing interferon-γ (IFN-γ) replicate in cell culture indistinguishably from control viruses; however, they replicate in vivo to low or undetectable levels, and are rapidly cleared even in immunodeficient animals. In an effort to develop safe and highly effective replication-competent VACV vectors, we established a system to inducibly express IFN-γ. Our SMART (safety mechanism assisted by the repressor of tetracycline) vectors are designed to express the tetracycline repressor under a constitutive VACV promoter and IFN-γ under engineered tetracycline-inducible promoters. Immunodeficient SCID mice inoculated with VACVs not expressing IFN-γ demonstrated severe weight loss, whereas those given VACVs expressing IFN-γ under constitutive VACV promoters showed no signs of infection. Most importantly, mice inoculated with a VACV expressing the IFN-γ gene under an inducible promoter remained healthy in the presence of doxycycline, but exhibited severe weight loss in the absence of doxycycline. In this study, we developed a safety mechanism for VACV based on the conditional expression of IFN-γ under a tightly controlled tetracycline-inducible VACV promoter for use in vaccines and oncolytic cancer therapies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23988330      PMCID: PMC3780884          DOI: 10.1073/pnas.1314483110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  Autoregulatory lentiviral vectors allow multiple cycles of doxycycline-inducible gene expression in human hematopoietic cells in vivo.

Authors:  M Centlivre; X Zhou; S M Pouw; K Weijer; W Kleibeuker; A T Das; B Blom; J Seppen; B Berkhout; N Legrand
Journal:  Gene Ther       Date:  2009-09-03       Impact factor: 5.250

2.  gpt-gus fusion gene for selection and marker in recombinant poxviruses.

Authors:  J X Cao; C Upton
Journal:  Biotechniques       Date:  1997-02       Impact factor: 1.993

3.  Vaccinia virus recombinants expressing chimeric proteins of human immunodeficiency virus and gamma interferon are attenuated for nude mice.

Authors:  L D Giavedoni; L Jones; M B Gardner; H L Gibson; C T Ng; P J Barr; T Yilma
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

4.  Vaccinia virus vectors with an inactivated gamma interferon receptor homolog gene (B8R) are attenuated In vivo without a concomitant reduction in immunogenicity.

Authors:  P H Verardi; L A Jones; F H Aziz; S Ahmad; T D Yilma
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

Review 5.  Smallpox vaccination: a review, part II. Adverse events.

Authors:  Vincent A Fulginiti; Arthur Papier; J Michael Lane; John M Neff; D A Henderson
Journal:  Clin Infect Dis       Date:  2003-07-10       Impact factor: 9.079

6.  One hundred base pairs of 5' flanking sequence of a vaccinia virus late gene are sufficient to temporally regulate late transcription.

Authors:  C Bertholet; R Drillien; R Wittek
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

7.  Vaccinia virus morphogenesis: a13 phosphoprotein is required for assembly of mature virions.

Authors:  Bethany Unger; Paula Traktman
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

8.  Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection.

Authors:  I A Ramshaw; M E Andrew; S M Phillips; D B Boyle; B E Coupar
Journal:  Nature       Date:  1987 Oct 8-14       Impact factor: 49.962

9.  Tetracycline repressor, tetR, rather than the tetR-mammalian cell transcription factor fusion derivatives, regulates inducible gene expression in mammalian cells.

Authors:  F Yao; T Svensjö; T Winkler; M Lu; C Eriksson; E Eriksson
Journal:  Hum Gene Ther       Date:  1998-09-01       Impact factor: 5.695

10.  Comparison of doxycycline delivery methods for Tet-inducible gene expression in a subcutaneous xenograft model.

Authors:  Christopher Cawthorne; Ric Swindell; Ian J Stratford; Caroline Dive; Arkadiusz Welman
Journal:  J Biomol Tech       Date:  2007-04
View more
  5 in total

1.  Inducible gene expression in tumors colonized by modified oncolytic vaccinia virus strains.

Authors:  Jochen Stritzker; Sascha Huppertz; Qian Zhang; Ulrike Geissinger; Barbara Härtl; Ivaylo Gentschev; Aladar A Szalay
Journal:  J Virol       Date:  2014-07-23       Impact factor: 5.103

2.  Doxycycline Inducible Melanogenic Vaccinia Virus as Theranostic Anti-Cancer Agent.

Authors:  Lorenz Kirscher; Xosé Luis Deán-Ben; Miriam Scadeng; Angelika Zaremba; Qian Zhang; Christina Kober; Thomas Felix Fehm; Daniel Razansky; Vasilis Ntziachristos; Jochen Stritzker; Aladar A Szalay
Journal:  Theranostics       Date:  2015-06-15       Impact factor: 11.556

3.  Repeatable, Inducible Micro-RNA-Based Technology Tightly Controls Liver Transgene Expression.

Authors:  Iulian I Oprea; Joana R Viola; Pedro M D Moreno; Oscar E Simonson; Sergey Rodin; Nathalie Teller; Karl Tryggvason; Karin E Lundin; Leonard Girnita; Carl Inge Edvard Smith
Journal:  Mol Ther Nucleic Acids       Date:  2014-07-01       Impact factor: 10.183

4.  Single dose of a replication-defective vaccinia virus expressing Zika virus-like particles is protective in mice.

Authors:  Brittany Jasperse; Caitlin M O'Connell; Yuxiang Wang; Paulo H Verardi
Journal:  Sci Rep       Date:  2021-03-22       Impact factor: 4.379

5.  Replication-inducible vaccinia virus vectors with enhanced safety in vivo.

Authors:  Caitlin M O'Connell; Brittany Jasperse; Caitlin J Hagen; Allison Titong; Paulo H Verardi
Journal:  PLoS One       Date:  2020-04-02       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.